Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Inv. presentation
Auditor change
|
|
Cellular Biomedicine Group, Inc. (CBMG)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/19/2021 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...|
Docs:
|
"AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CELLULAR BIOMEDICINE GROUP, INC. ARTICLE ONE The name of the corporation is Cellular Biomedicine Group, Inc. . ARTICLE TWO The address of the Corporation’s registered office is at Suite 302, 4001 Kennett Pike, County of New Castle, Wilmington, DE 19807. The name of its registered agent at such address is Maples Fiduciary Services Inc. ARTICLE THREE The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware . ARTICLE FOUR The total number of shares which the Corporation shall have the authority to issue is one thousand , all of which shall be shares of common stock, with a par value of one cent per share, and are to be of one ...",
"ARTICLES OF INCORPORATION / BYLAWS",
"CELLULAR BIOMEDICINE GROUP, INC. ANNOUNCES COMPLETION OF MERGER ROCKVILLE, MD and SHANGHAI, China – Cellular Biomedicine Group, Inc. today announced the completion of the merger of the Company with CBMG Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of CBMG Holdings, an exempted company with limited liability incorporated under the laws of the Cayman Islands , pursuant to the previously announced Agreement and Plan of Merger , dated as of August 11, 2020, by and among the Company, Parent and Merger Sub. Under the terms of the Merger Agreement, which was approved by the Company’s stockholders at its special meeting of stockholders held on February 8, 2021, each share of the Company’s common stock, par value $0.001 per share , issued and outstanding immediately prior ..." |
|
| 02/08/2021 |
8-K
| Quarterly results |
| 02/01/2021 |
8-K
| Quarterly results |
| 12/04/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 10/26/2020 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"BRIDGE LOAN AGREEMENT This BRIDGE LOAN AGREEMENT is made and entered into on October 23, 2020 , by and among the following parties: 1. Cellular Biomedicine Group, Inc., a Delaware corporation ; 2. TF I Ltd. . The Company and the Lender are collectively referred to below as the “Parties” and each a “Party”. RECITALS A. The Company requires an infusion of funds in order to conduct its business activities. B. The Lender is willing to make available the Loan to the Company, on the terms set forth below. NOW, THEREFORE, in consideration of the premises set forth above, the mutual promises and covenants set forth herein and other good and valuable consideration, the parties agree as follows: 1. THE LOAN 1.1 Subject to the terms and conditions hereunder, the Lender agr...",
"BRIDGE LOAN AGREEMENT This BRIDGE LOAN AGREEMENT is made and entered into on October 23, 2020 , by and among the following parties: 1. Cellular Biomedicine Group, Inc., a Delaware corporation ; 2. Yunfeng Capital Limited . The Company and the Lender are collectively referred to below as the “Parties” and each a “Party”. RECITALS A. The Company requires an infusion of funds in order to conduct its business activities. B. The Lender is willing to make available the Loan to the Company, on the terms set forth below. NOW, THEREFORE, in consideration of the premises set forth above, the mutual promises and covenants set forth herein and other good and valuable consideration, the parties agree as follows: 1. THE LOAN 1.1 Subject to the terms and conditions hereunder, ..." |
|
| 08/28/2020 |
8-K
| Quarterly results |
| 08/12/2020 |
8-K
| Quarterly results |
| 07/13/2020 |
8-K
| Quarterly results |
| 06/29/2020 |
8-K
| Quarterly results |
| 06/22/2020 |
8-K
| Quarterly results |
| 04/03/2020 |
8-K
| Regulation FD Disclosure |
| 02/24/2020 |
8-K
| Quarterly results |
| 01/29/2020 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 12/30/2019 |
8-K
| Quarterly results |
| 12/09/2019 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits|
Docs:
|
"Presentation",
"Cellular Biomedicine Group Presents First Clinical Data of IIT Phase 1 Trial of C-CAR088, a Novel BCMA CAR-T, at the 61st Annual Meeting of the American Society of Hematology – Five Patients were included in the analysis; all five patients showed clinical improvement in as early as two weeks and SHANGHAI, China, December 7th, 2019 – Cellular Biomedicine Group Inc. , a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies, announced early data from its ongoing investigator initiated trial at an oral presentation titled “Novel Anti-BCMA CAR-T for Relapsed or Refractory Multiple Myeloma” at the 61st American Society of Hematology annual meeting on December 7, 2019 in Orlando, Florida. ABSTRACT DETAILS C-CAR088 is a novel ant..." |
|
| 11/12/2019 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 11/08/2019 |
8-K
| Quarterly results |
| 10/17/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/03/2019 |
8-K
| Quarterly results |
| 09/27/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 09/12/2019 |
8-K
| Quarterly results |
| 09/11/2019 |
8-K
| Quarterly results |
| 08/29/2019 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 07/23/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Cellular Biomedicine Group to Report Second Quarter 2019 Results on August 6, 2019 and SHANGHAI, China, July 23, 2019 – Cellular Biomedicine Group Inc. , a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it will release its financial results for the second quarter ended June 30, 2019 after the market closes on Tuesday, August 6, 2019. The Company will host a conference call and webcast with the investment community on Tuesday, August 6th at 4:30 p.m. Eastern Time / Wednesday, August 7th at 4:30 a.m. China Standard Time featuring remarks by Tony Liu, Executive Director, CEO and CFO of CBMG. What: Cellular Biomedicine Group Second Quarter 2019 Results Conference Call Date: Tuesday, Au..." |
|
| 06/17/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 05/16/2019 |
8-K
| Resignation/termination of a director |
| 04/29/2019 |
8-K
| Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Cellular Biomedicine Group Announces Results of 2019 Annual Meeting of Stockholders , and SHANGHAI, CHINA, April 29, 2019 -- Cellular Biomedicine Group, Inc. , a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the voting results of its 2019 Annual Meeting of Stockholders, held on April 26, 2019 in . Approximately 79% of the Company’s outstanding shares were represented at the 2019 Annual Meeting. The following business items were approved by a strong majority at the Annual Meeting: 1. Elect two “Class I” directors, each of whom will be elected for a term of three years; 2. Ratify the appointment of BDO China Shu Lun Pan Certified Public Accountants LLP as our independent re..." |
|
| 04/25/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Cellular Biomedicine Group to Report First Quarter 2019 Results and Host Conference Call on May 1, 2019 and SHANGHAI, China, April 25, 2019 – Cellular Biomedicine Group Inc. , a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it will release its financial results for the first quarter ended March 31, 2019 before the market opens on Wednesday, May 1, 2019. The Company will host a conference call and webcast with the investment community on Wednesday, May 1st at 8:30 a.m. Eastern Time / 8:30 p.m. China Standard Time featuring remarks by Tony Liu, Executive Director, CEO and CFO of CBMG. What: Cellular Biomedicine First Quarter 2019 Results Conference Call Date: Wednesday, May 1, 2019 ..." |
|
| 04/23/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 03/28/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Cellular Biomedicine Group Announces Annual Meeting of Stockholders SHANGHAI, China and , Mar. 28, 2019 — Cellular Biomedicine Group Inc. , a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Annual Meeting of Stockholders will be held on Friday, April 26, 2019. The meeting will be held at the Company’s office at 1345 Avenue of the Americas, 15th Floor, 10105 at 9:00 a.m. EDT. Stockholders of record as of March 8, 2019, the record date for the meeting, are authorized and asked to vote in the manner directed in the proxy materials. A stockholder, once having received his/her proxy notice and access card, may view the proxy statement and related materials online or request a printed..." |
|
| 03/22/2019 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Underwriting Agreement, by and among Cellular Biomedicine Group, Inc., Cantor Fitzgerald & Co. and Robert W. Baird & Co. Incorporated, as representatives of the several underwriters",
"Opinion of Ellenoff Grossman & Schole LLP",
"Cellular Biomedicine Group Announces Pricing of Public Offering of Common Stock , March 21, 2019 -- Cellular Biomedicine Group, Inc. , a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the pricing of an underwritten public offering of 1,029,412 shares of its common stock at a public offering price of $17.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to 154,411 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. Closing of the offering is expected to occur on or about March 25, 2019, subject to customary closing conditions. The gross proceeds to CBMG from this offering are expected ...",
"ADDITIONAL BUSINESS INFORMATION" |
|
| 03/20/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 03/01/2019 |
8-K
| Quarterly results |
|
|
|